Skip to main content

Table 3 Multivariable Cox proportional hazards model

From: Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

Variable

Progression-free survival

Overall survival

 

Hazard ratio (95% CI)

Pvalue

Hazard ratio (95% CI)

Pvalue

HR+ vs. HR-

0.63 (0.46 to 0.86)

0.003

0.51 (0.34 to 0.79)

0.002

HER-2 amplified/overexpressed vs. HER-2 normal

0.52 (0.34 to 0.79)

0.002

0.39 (0.21 to 0.73)

0.003

Visceral vs. other metastases

1.39 (0.92 to 2.05)

0.095

1.77 (0.95 to 3.30)

0.074

Number of metastatic sites (1 vs. 3 vs. ≥ 3)

0.88 (0.70 to 1.10)

0.266

0.67 (0.47 to 0.95)

0.024

Circulating tumor cells (< 5 versus ≥ 5)

0.58 (0.43 to 0.79)

< 0.001

0.40 (0.26 to 0.62)

< 0.001

  1. CI, confidence interval; HER-2, human epidermal growth factor receptor-2; HR+, estrogen receptor-positive and/or progesterone receptor-positive; HR-, both estrogen receptor-positive and progesterone receptor-negative.